NOVN Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Novartis (SWX: NOVN)
›
Novartis (SWX: NOVN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 75,267 employees.
The shares were at 127.44 CHF on 20 November 2026, up 25.7% over 52 weeks. Its 52-week range is 99.45 CHF to 137.00 CHF: the price is 7.0% below the high and 28.1% above the low.
At a market capitalisation of 241.29B CHF, it trades at 30.6 times trailing earnings and 15.5 times forward earnings. The median trailing P/E of its 18 largest Drug Manufacturers - General peers is 25.2, a premium of 22% for NOVN. It pays a dividend yielding 2.91% (it pays out 87% of its earnings), against a median of 2.45% among the dividend payers in that peer group.
Novartis reports return on equity of 30.3%, an operating margin of 34.0% and revenue up 4.7% year over year.
Its debt exceeds its cash by 39.44B USD, a debt-to-equity ratio of 0.77. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 22 analysts cover the stock, with an average rating of Hold; their mean price target of 128.78 CHF is 1.1% above the current price. The next earnings report is expected on 3 February 2027.